Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ

LAMIVUDINE;ZIDOVUDINE;EFAVIRENZ

Standard Dose
150MG;300MG;600MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ is listed in Drugs@FDA under application 206040 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE;ZIDOVUDINE;EFAVIRENZ Form and strength TABLET;ORAL - 150MG;300MG;600MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-09-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ is listed in Drugs@FDA under application 206040 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE;ZIDOVUDINE;EFAVIRENZ Form and strength TABLET;ORAL - 150MG;300MG;600MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-09-04 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.